Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults

Inclusion Criteria: * Male or female \>18 years of age * Participant must have a diagnosis of an infection (HAP/VAP, cUTI, cIAI, BSI) due to confirmed carbapenem-resistant aerobic Gram-negative pathogens, requiring administration of IV antibacterial therapy * Participant who had received appropriate prior empiric antibacterial therapy for a carbapenem-resistant pathogen must meet at least 1 of the following criteria: no or no more than 24h; worsening of objective symptoms or signs after at least 48 hours of antibacterial therapy; no change of objective symptoms or signs after at least 72 hours of antibacterial therapy. * Capable of giving signed informed consent Exclusion Criteria: * Other medical or psychiatric condition may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. * Participant is expected to require more than 21 days of treatment * Participants who need more than 3 systemic antibiotics as part of best available treatment (BAT) * Previous administration with an investigational drug within 30 days or 5 half lives preceding the first dose of study intervention used in this study (whichever is longer). * Participant is pregnant or breastfeeding. * Acute Physiology and Chronic Health Evaluation (APACHE) II score \>30 or \<10 using the most recent available data.